{"organizations": [], "uuid": "f66aff7ce694e836d13930a9f0191cdbdd89a62c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180122.html", "section_title": "Archive News &amp; Video for Monday, 22 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-indias-shilpa-medicare-says-us-fda/brief-indias-shilpa-medicare-says-u-s-fda-issues-3-483-observations-to-cos-karnataka-units-idUSFWN1PH06X", "country": "US", "domain_rank": 408, "title": "BRIEF-India's Shilpa Medicare Says U.S. FDA Issues 3 483 Observations To Co's Karnataka Units", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.12, "site_type": "news", "published": "2018-01-22T16:55:00.000+02:00", "replies_count": 0, "uuid": "f66aff7ce694e836d13930a9f0191cdbdd89a62c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-indias-shilpa-medicare-says-us-fda/brief-indias-shilpa-medicare-says-u-s-fda-issues-3-483-observations-to-cos-karnataka-units-idUSFWN1PH06X", "ord_in_thread": 0, "title": "BRIEF-India's Shilpa Medicare Says U.S. FDA Issues 3 483 Observations To Co's Karnataka Units", "locations": [], "entities": {"persons": [], "locations": [{"name": "karnataka", "sentiment": "none"}, {"name": "us", "sentiment": "none"}, {"name": "raichur", "sentiment": "none"}, {"name": "karnataka", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "shilpa medicare says u.s. fda", "sentiment": "negative"}, {"name": "shilpa medicare ltd", "sentiment": "negative"}, {"name": "observations to co", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 22 (Reuters) - Shilpa Medicare Ltd:\n* US FDA COMPLETED INSPECTION OF COâ€˜S API FACILITIES UNIT-I AND UNIT-II LOCATED AT RAICHUR, KARNATAKA\n* SAYS INSPECTION CLOSED BY US FDA WITH THREE 483 OBSERVATIONS\n* IN PROCESS OF SUBMISSION OF CAPA PLAN TO REGULATOR WITHIN STIPULATED TIMELINES IN RESPONSE TO FORM 483 ISSUED Source text - bit.ly/2F0R0U9 Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "http://bit.ly/2F0R0U9"], "published": "2018-01-22T16:55:00.000+02:00", "crawled": "2018-01-23T18:05:37.009+02:00", "highlightTitle": ""}